PCSA Processa Pharmaceuticals, Inc.
Company Updates ·
Processa said the FDA cleared an IND for a study of VT-7208 in chronic spontaneous urticaria, expected to enroll approximately 120 adults, and that its cash should fund operations into the second half of 2029.
Processa said it acquired Vidya Therapeutics, whose lead asset is the BTK inhibitor VT-7208, alongside a concurrent private placement of approximately $200 million.
Nasdaq has given Processa until February 2, 2026 to bring its share price back to at least $1, a second 180-day period. The company says it will consider a reverse stock split, and the filing gives no recent share price to show how far it is from the threshold.
Processa says the private placement closed August 6, 2025, with LifeSci Capital LLC as exclusive placement agent. The company also says it is evaluating corporate cryptocurrency treasury strategies.
Processa filed a new prospectus supplement that lets it sell up to $5,239,073 of stock through its at-the-market program with A.G.P./Alliance Global Partners. Its shares closed at $0.2497 on July 22, 2025, down from $0.40 on June 11, 2025, the date its public float was measured.
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$13.6 million | -$11.9 million |
| Cash from operations | -$11.4 million | -$11.2 million |
| Cash and equivalents | $5.5 million | $1.2 million |
Our latest story on this, dated Aug 8, 2025: "Processa Pharmaceuticals gets second 180-day Nasdaq period to fix bid price". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 29, 2026: "Processa acquires Vidya Therapeutics with $200 million placement". The story links the filing or release it is based on. Read the story.
Processa Pharmaceuticals, Inc. trades under the ticker PCSA on NASDAQ.
Processa Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Processa Pharmaceuticals, Inc. is 1533743. Its filings are on SEC EDGAR.
2,793,386 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Processa Pharmaceuticals, Inc. under United States.
Our directory classifies Processa Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Processa Pharmaceuticals, Inc. is US74275C4033.
aibio.space lists Processa Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Processa Pharmaceuticals, Inc. reported a net loss of $13.6 million for the fiscal year ended Dec 31, 2025, and used $11.4 million of cash in operations, per its annual report to the SEC.
$196,325 in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Processa Pharmaceuticals, dated Oct 29, 2026: "Processa clears VT-7208 CSU IND and names a new executive chair". Processa said the FDA cleared an IND for a study of VT-7208 in chronic spontaneous urticaria, expected to enroll approximately 120 adults, and that its cash should fund operations into the second half of 2029. Source.
From our story of Oct 29, 2026: Processa said the FDA cleared an IND for a study of VT-7208 in chronic spontaneous urticaria, expected to enroll approximately 120 adults, and that its cash should fund operations into the second half of 2029. Source.
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,1.02,2.01,3.02,5.02,5.03,7.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form S-1. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio